30. Top‐ranked antidepressants for serious adverse events analysis.
| Odds ratio (95% CI) | Mean rank | Credible intervals | ||
| 2.5% | 97.5% | |||
| Desvenlafaxine high dose | 0.51 (−0.27 to 1.29) |
11.4 | 4 | 24 |
| Milnacipran dose unable to be categorised | 0.66 (−0.95 to 2.27) |
15.5 | 2 | 36 |
| Duloxetine low dose | 0.89 (−0.05 to 1.83) |
18.5 | 6 | 32 |
| Duloxetine high dose | 0.92 (0.43 to 1.41) |
18.8 | 9 | 29 |
| Milnacipran standard dose | 0.94 (0.31 to 1.57) |
19.3 | 9 | 31 |
| Mirtazapine standard dose | 0.99 (−0.83 to 2.81) |
10.0 | 3 | 38 |
| Milnacipran high dose | 1.08 (0.55 to 1.61) |
21.6 | 11 | 32 |
| Duloxetine standard dose | 1.16 (0.71 to 1.61) |
22.8 | 13 | 32 |
| Esreboxetine standard dose | 2.25 (−0.69 to 5.19) |
26.7 | 4 | 41 |
| Esreboxetine high dose | 2.75 (−0.35 to 5.85) |
28.3 | 4 | 41 |
| CI: confidence interval | ||||